

REMARKS

Claims 1; 6; and 13 have been amended. Claims 3 and 11 have been canceled. Claims 2; 4; 5; 9; 12; 16; 24; 28; 30; and 33 were previously canceled. New dependent claims 38 to 42 have been added. The title has been amended to reflect the subject matter defined in the amended claims.

Claims 7; 8; 10; 14; 15; 17; 18; 19; 20; 21; 22; 23; 25; 26; 27; 29; 31; 32; 34; 35; 36; and 37 have previously withdrawn as being directed to a non-elected invention or species. Applicant seeks the opportunity to consider reinstatement of certain withdrawn claims upon allowance of allowable subject matter

Claims 1; 6; 13; and 38 to 42 remain in the application. Among these, claims 1 and 6 are independent method claims.

In response to the scope of enablement rejection, claims 1 and 6 have been amended to define treatment of breast cancer, colon cancer, or prostate cancer. The Examiner acknowledges that this subject matter is enabled by the specification.

In response to written description rejection, claims 1 and 6 have been amended to define perfluorooctanoic acid, or a salt of perfluorooctanoic acid, or an ester formed between perfluorooctanoic acid and an alcohol of formula R^1OH , or an ester formed between perfluorooctanoic acid and a thiol of formula R^1SH , wherein R^1 consists essentially of C_{1-16} alkyl groups or C_{6-10} acryl groups. Support for this terminology is found, e.g., on Specification Page 5, line 29 to Specification Page 6, line 18.

Support for new claims 38 to 41 is found, e.g., on Specification Page 6, lines 17 and 18. Support for the amendment to claim 13 and new claim 42 is found, e.g., Specification Page 5, lines 23 to 27.

Claims 1; 6 and 13 stand rejected based upon Revici et al (US 4,624,851). Revici does not teach or suggest the treatment of breast cancer, colon cancer, or prostate cancer, as defined in the amended claims. Revici expressly discloses the treatment of some cancer symptoms, and expressly excludes treatment of the cancer itself. See, e.g., col. 1, lines 7 to 14 and lines 48 to 49. Furthermore, nowhere does Revici teach or suggest, in particular, the treatment of cancer of the breast, or colon, or prostate, as defined in the amended claims.

Application Serial No. 10/526,025

Amendment B

Page - 8 -

Claims 1; 6; 13; and 38 to 42 are therefore believed to be in condition for allowance.

Respectfully Submitted,

By


Daniel D. Ryan

Registration No. 29,245

RYAN KROMHOLZ & MANION, S.C.

Post Office Box 26618

Milwaukee, Wisconsin 53226

(262) 783 - 1300

Customer No.: 26308

Enclosures: Amendment Transmittal Letter
 Return Postcard